This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Treatment: The Right Royal for the Castle?
Treatment: The Right Royal for the Castle?
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I'm Dr. Corey Casper. Here with me today is Dr. Sudipto Mukherjee.
Let's get right into today's topic, Dr. Mukherjee. What can you tell us about treatment guidelines that are in place for treating idiopathic multicentric Castleman’s disease, or iMCD?
Most of the evidence in support of trading iMCD comes from the international evidence-based consensus treatment guidelines for iMCD that was just recently published in Blood in 2017 [Blood. 2017; 129(12):1646-1657.]. And based on those treatment guidelines, all patients diagnosed with iMCD are recommended to start treatment on anti-IL-6 monoclonal antibody therapy with siltuximab. Siltuximab, in fact, is the only FDA-approved drug for managing iMCD in the US and is also recommended as a first-line therapy by National Comprehensive Cancer Network. It is administered as an intravenous infusion once every 3 weeks.
However, initiating therapy and what is the right therapy for each patient depends upon the underlying clinical condition of the disease and the availability of the drugs. Up to 10% to 20% of iMCD patients can present with severe iMCD, which is marked by multi-organ failure and requiring life support such as dialysis, intubation, vasopressor support. And in such cases, where there's a cytokine storm with a very high circulating levels of IL-6, a more aggressive approach might be needed for a quick disease control. And in most such cases, high-dose steroids with siltuximab as the initial combination regimen might be a reasonable approach. If the patient declines on this initial combination regimen or we do not see any improvement within a week, then in those cases, it may be reasonable to employ multi-agent chemotherapy based on lymphoma or myeloma-based regimens.
Additionally, siltuximab is not available in all countries around the globe. Where siltuximab is not available or is not approved by the regulatory agencies, it is reasonable to use tocilizumab. For example, tocilizumab is the primary IL-6 monoclonal antibody used in Japan. And in some countries where neither of these drugs are available or approved, it is reasonable to start with rituximab, which has been reported in several case series.
With rituximab there is published data showing a role for rituximab, but it seems like it is most effective in patients with iMCD who do not have any marked cytokine symptomatology or marked organ dysfunction or lab abnormalities. However, the caveat is rituximab has never been rigorously tested in clinical trial like siltuximab, and wherever possible, siltuximab should always be the preferred first-line therapy. In most of these patients, they do end up getting on steroids, and steroids are useful adjunctive therapy for initial disease control, but should be quickly discontinued because of their long-term side effects.
Importantly, in all iMCD patients treated with IL-6-directed therapy, about 50% would at some point fail to respond to these therapies. And for these patients, currently, there are no standard of care. A variety of agents being tested in clinical trials are considered candidate targets. One of the best evidence-based data suggests a role for mTOR inhibitors such as sirolimus that is currently being tested in a clinical trial. Other candidate targets include CXCL4 inhibitors or targeting the JAK/STAT pathway. There are various other agents that have been used to manage these patients. And there are case reports in the literature, but none of them have been rigorously tested or validated.
Thank you, Dr. Mukherjee. You did a wonderful job summarizing very complicated treatments and options for Castleman’s disease. Just to sort of amplify what you said, so first and foremost, this is a disease that is mediated by making too much interleukin-6. So by international guidelines, the first line of therapy is an anti-IL-6 inhibitor. Siltuximab is the medication that has been tested in randomized controlled trials and licensed by the FDA for this purpose. There are other IL-6 inhibitors that have been less rigorously studied but are more widely available in other parts of the world, like tocilizumab. These are options as well. The majority of patients will respond to siltuximab, but among those who don’t, there are other options in the future.
So this has been a great initial bite-sized discussion. Unfortunately, our time is up. Thank you for listening.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Corey Casper, MD, MPH
Clinical Professor of Medicine and Global Health
University of Washington
Affiliate Professor, Fred Hutch Cancer Center
Research: Amyris, ImmunityBio (IBRX), Janssen
Ownership Interest: Viracta Therapeutics
Receives Royalties: UpToDate
Patent Holder: AAHI
Consulting Fees: EUSA Pharma
Sudipto Mukherjee, MD, PhD, MPH
Director, Rare Cancers & Blood Diseases
Cleveland Clinic Taussig Cancer Institute
Research: BMS/Celgene, Jazz Pharma, Novartis
Receives Royalties: McGraw Hill
Consulting Fees: BioPharm, Blueprint Medicines, BMS/Celgene, Genentech and AbbVie, EUSA, Novartis
- Cindy Davidson has nothing to disclose.
- Stephen Chavez has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Mara Siegel has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Discuss the clinical burden and impact associated with a delayed diagnosis of Castleman disease
- Improve the speed and accuracy of a diagnosis of Castleman disease through increased recognition of its clinical presentation and knowledge of published diagnostic criteria
- Incorporate guideline-concordant care into the treatment of patients with Castleman disease
- Employ shared decision-making strategies to increase patient participation and promote advocacy, clinical trial enrollment, and research
This activity is designed to meet the educational needs of US hematologist oncologists, rheumatologists, infectious disease specialists, immunologists, and other HCPs who are involved in diagnosing, managing, and treating iMCD.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Recordati.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.